Technology

Developing technology may offer marked improvements in surgical precision

Physicians explore how other specialties adopted and integrated remote monitoring into plans.

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

Earlier this year, the US Centers for Disease Control and Prevention issued an advisory, sounding the alarm for an outbreak of a drug resistant strain of the bacteria Pseudomonas aeruginosa that was connected to the use of artificial tears.

The company has released a video presentation that highlights combining genetic markers with high-resolution retinal imaging to assist in the detection and treatment of blindness and multiple systemic diseases.

Noncontact esthesiometry screens for all levels of neurotrophic keratitis.

According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.

Study demonstrates power of IRIS Registry for evaluation of safety, efficacy

According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.

According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.

According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.

The Icahn School of Medicine at Mount Sinai opened the Center for Ophthalmic Artificial Intelligence and Human Health, which is dedicated to advancing artificial intelligence to offer faster diagnosis and treatment.

Orbis International physician spotlights the latest trends for cataract surgery training.

Researchers are involved in the development of Eye2Gene, an AI system capable of identifying the genetic cause of IRDs from retinal scans.

Scientists hope to develop of novel AI solutions for the prediction of DPN using corneal OCT images.

IIT Kanpur licensed the technology to Reliance Life Sciences Pvt. Ltd. and this marks the first time a gene therapy related technology has been developed and transferred from an academic institution to a company in India.

According to the company, its latest laser recently received FDA clearance and CE mark approval.

Debate continues over the best way to apply the treatment option.

The scanning laser features a wireless user interface, no external fiber and utilizes MEMS technology.

The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

Ophthalmology Times® talked with T. Y. Alvin Liu, MD, about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

According to the companies, Boehringer Ingelheim will use RetinAI’s tools to develop treatments for GA, applying the company’s artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.

The Iridex PASCAL combines industry-leading speed and precision pattern scanning, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and now, MicroPulse Technology, in an integrated laser platform using half the footprint of its predecessor.